Publication Name	World Journal of Clinical Oncology
Manuscript ID	6166
Country	India

Received	2013-10-07 10:24
Peer-Review Started	2013-10-07 11:08
To Make the First Decision	2013-11-12 14:32
Return for Revision	2013-11-12 19:18
Revised
Second Decision	2014-01-20 08:49
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-01-20 09:55
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-02-26 14:55
Typeset the Manuscript	2014-05-07 14:39
Publish the Manuscript Online	2014-05-12 18:06

ISSN	2218-4333 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Systemic treatment strategies for triple-negative breast cancer
Manuscript Source	Invited Manuscript
All Author List	Budhi Singh Yadav, Suresh C Sharma, Priyanka Chanana and Swaty Jhamb
Funding Agency and Grant Number
Corresponding Author	Dr. Budhi Singh Yadav, Assistant Professor, Department of Radiotherapy, PGIMER, Sector 12, Chandigarh 160012, India. drbudhi@gmail.com
Key Words	Breast cancer; Triple negative; Basal like; BRCA1; Poly (ADP-ribose) polymerase 1; Targeted therapy; Chemotherapy
Core Tip	Breast cancer is a heterogeneous disease entity with different biological characteristics and clinical behavior. There are no treatment guidelines for triple-negative breast cancer (TNBC). TNBCs are sensitive to taxanes and anthracyclins but there are high rates of local and systemic relapses. Recently there has been great interest in platinum agents, either alone or in combination with poly adenosine diphosphate polymerase 1 inhibitors. Combinations of ixabepilone and capecitabine have shown improved response rates (RRs). Other useful drugs are antiangiogenic agents, tyrosine kinase and epidermal growth factor receptor inhibitors with variable RRs but no survival benefit. In this review, we discuss various systemic treatment strategies available for TNBC and the benefit from each of them.
Publish Date	2014-05-12 18:06
Citation	Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014; 5(2): 125-133
URL	http://www.wjgnet.com/2218-4333/full/v5/i2/125.htm
DOI	http://dx.doi.org/10.5306/wjco.v5.i2.125

Full Article (PDF)	WJCO-5-125.pdf
Full Article (Word)	WJCO-5-125.doc
Manuscript File	6166-Review.doc
Answering Reviewers	6166-Answering reviewers.pdf
Copyright License Agreement	6166-Copyright Assignment.pdf
Non-Native Speakers of English Editing Certificate	6166-Language certificate.pdf
Peer-review Report	6166-Peer review(s).pdf
Scientific Editor Work List	6166-Scientific editor work list.doc